Company Overview - Yuneng International (01298.HK) reported a closing price of HKD 1.1 per share, with a significant increase of 15.79% and a trading volume of 3,000 shares, totaling HKD 3,280 [1] - The company has experienced a cumulative increase of 35.71% over the past month, but a year-to-date decline of 4.04%, underperforming the Hang Seng Index by 24.48% [2] Financial Performance - For the fiscal year ending December 31, 2024, Yuneng International achieved total revenue of HKD 534 million, reflecting a year-on-year growth of 68.67% [2] - The net profit attributable to shareholders was HKD 454,700, marking a substantial increase of 109.88% [2] - The company's gross margin stands at 5.18%, with a debt-to-asset ratio of 60.43% [2] Valuation and Industry Comparison - Currently, there are no institutional investment ratings for Yuneng International [3] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -0.03x, with a median of 1.37x [3] - Yuneng International's P/E ratio is exceptionally high at 532.92x, ranking 53rd in the industry, compared to peers such as Jingjiu Kangliao (0.38x), Juxing Medical Holdings (0.4x), and others [3] Business Operations - Yuneng International is a Bermuda-registered investment holding company, listed on the Singapore Exchange in 2004 and on the Hong Kong Stock Exchange in 2011 [3] - The company primarily engages in the distribution and after-sales service of various analytical instruments in China, offering solutions for scientific analysis and testing [3] Upcoming Events - The company is scheduled to disclose its mid-year report for the fiscal year 2025 on August 18, 2025 [4] - A preliminary announcement indicates an expected decline in mid-year earnings for 2025, with a projected loss of approximately HKD 3 million to HKD 2.5 million, representing a year-on-year decrease of 733.33% to 900% [4]

Group 1 - The core viewpoint of the news highlights the significant stock performance of Yuneng International, which saw a 75.71% increase in share price, despite a year-to-date decline of 29.29% [1] - As of December 31, 2024, Yuneng International reported total revenue of 534 million yuan, representing a year-on-year growth of 68.67%, and a net profit attributable to shareholders of 454,700 yuan, with a growth of 109.88% [1] - The company's gross profit margin stands at 5.18%, and its debt-to-asset ratio is 60.43% [1] Group 2 - Currently, there are no institutional investment ratings for Yuneng International [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.39 times, with a median of 1.17 times, while Yuneng International's P/E ratio is significantly higher at 392.68 times, ranking 53rd in the industry [2] - Yuneng International is a Bermuda-registered investment holding company, primarily engaged in the distribution and after-sales service of various analytical instruments in China, including chromatography, spectrometers, and electron microscopes [2]

Core Viewpoint - Yuneng International (01298) reported a significant increase in revenue for the fiscal year 2024, achieving a total revenue of HKD 571 million, representing a year-on-year growth of 65.64% and turning a profit with a net profit of HKD 491,000 [3] Financial Performance - The company’s operating cash flow was negative at HKD -75.77 million, a decrease of HKD 89.77 million compared to the previous year [30] - Basic earnings per share were HKD 0.0018, with a weighted average return on equity of 0.3%, an increase of 3.25 percentage points year-on-year [26] - The price-to-earnings ratio (TTM) is approximately 392.68, with a price-to-book ratio of 1.17 and a price-to-sales ratio of 0.33 as of April 29 [3] Revenue Composition - For 2024, the revenue composition was HKD 524.5 million from the supply chain business and HKD 52.1 million from the distribution business [21] - In 2023, the revenue from the supply chain business was HKD 284.6 million, indicating growth in this segment [23] Asset and Liability Changes - As of the end of 2024, cash and cash equivalents decreased by 45.23%, while accounts receivable increased by 52.21% and inventory rose by 78.27% [38] - Short-term borrowings increased by 68.13%, and accounts payable rose by 86.26%, indicating a significant rise in liabilities [41] - The current ratio was reported at 1.49, and the quick ratio was 1.2 [45]